See more : Hyundai Futurenet Co., Ltd (126560.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Calyxt, Inc. (CLXT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Calyxt, Inc., a leading company in the Packaged Foods industry within the Consumer Defensive sector.
You may be interested
- Susco Public Company Limited (SUSCO.BK) Income Statement Analysis – Financial Results
- Nissan Chemical Corporation (NNCHY) Income Statement Analysis – Financial Results
- Federal National Mortgage Association (FNMAO) Income Statement Analysis – Financial Results
- Sociedad Química y Minera de Chile S.A. (SQM-B.SN) Income Statement Analysis – Financial Results
- Sical Logistics Limited (SICALLOG.BO) Income Statement Analysis – Financial Results
Calyxt, Inc. (CLXT)
About Calyxt, Inc.
Calyxt, Inc., a synthetic biology company, engages in delivering plant-based solutions primarily to the agriculture end market in the United States. The company is involved in the development of improved digestibility alfalfa; hemp; and wheat with a higher fiber content. It has a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and internationally. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 0.00 | 28.56M | 35.13M | 9.28M | 0.00 | 0.00 | 200.00K | 751.00K |
| Gross Profit | 157.00K | -2.57M | -11.28M | -1.98M | 236.00K | 508.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 100.00% | -9.89% | -47.28% | -27.19% | 100.00% | 100.00% | 49.87% | 40.96% |
| Research & Development | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 5.57M | 45.00K | 252.00K | 1.34M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 1.53M | 810.00K | 3.24M | 3.21M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -22.37M | -28.52M | -40.59M | -36.47M | -28.12M | -25.79M | -11.74M | -5.48M |
| EBITDA Ratio | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,830.08% | -5,005.51% | -2,941.35% | -430.90% |
| Operating Income | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -7.09M | -114.00K | 1.56M | 1.49M | 1.48M | -190.00K | 28.00K | 186.00K |
| Net Income | -9.80M | -29.09M | -46.40M | -41.10M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -6,243.95% | -111.92% | -194.54% | -563.35% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| EPS Diluted | -10.66 | -38.81 | -68.47 | -62.64 | -0.91 | -1.12 | -0.45 | -0.22 |
| Weighted Avg Shares Out | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
| Weighted Avg Shares Out (Dil) | 919.95K | 749.52K | 677.65K | 656.11K | 30.68M | 23.15M | 26.60M | 26.60M |
Will Calyxt (CLXT) Report Negative Earnings Next Week? What You Should Know
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt Announces New Strategic Direction to Provide Sustainable, Plant-Based Synthetic Biology Solutions to Expanded Group of End Markets and Diversified Base of Customers
ROSEVILLE, Minn., Oct. 5, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biotechnology company, today announced the launch of a strategic initiative that will focus the Company on engineering synthetic biology solutions for a diversified base of customers across...
Calyxt Seeks To Develop Palm Oil Alternative
Calyxt Inc (NASDAQ: CLXT) has entered into a research collaboration with a food ingredient manufacturer based in Asia to develop an improved soybean to produce oil as a commercial alternative to palm oil. As part of the research collaboration, Calyxt will receive cash...
Calyxt Announces Collaboration with Leading Global Food Ingredient Manufacturer to Develop Palm Oil Alternative
ROSEVILLE, Minn., Sept. 28, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based technology platform company, today announced it entered into a research collaboration with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of...
Calyxt, Inc. (CLXT) CEO Michael Carr on Q2 2021 Results - Earnings Call Transcript
Calyxt, Inc. (CLXT) CEO Michael Carr on Q2 2021 Results - Earnings Call Transcript
Calyxt: Q2 Earnings Insights
Shares of Calyxt (NASDAQ:CLXT) rose in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 36.36% over the past year to ($0.21), which missed the estimate of ($0.19).
Calyxt to Present at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021
ROSEVILLE, Minn., Aug. 4, 2021 /PRNewswire/ -- Calyxt, Inc. (Nasdaq: CLXT), a plant-based biotechnology platform company, today announced that management will present at the Canaccord Genuity 41st Annual Growth Conference at 11:00 a.m.
Calyxt (CLXT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Calyxt (CLXT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Calyxt to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:30 p.m. Eastern Time
ROSEVILLE, Minn., July 19, 2021 /PRNewswire/ -- Calyxt, Inc. (NASDAQ: CLXT) will hold a conference call on Thursday, August 5, 2021 at 4:30 p.m.
Calyxt Appoints Michael A. Carr As CEO
Biotechnology company Calyxt Inc (NASDAQ: CLXT) has appointed Michael A. Carr as President and Chief Executive Officer, effective July 27, 2021.
Source: https://incomestatements.info
Category: Stock Reports